Stocks · News reference

Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45

Sep 1, 2026, 2:49 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 1, 2026, 2:49 PM
Checked: Sep 1, 2026, 2:49 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 5, 2026, 2:01 PMBenzinga Newsdesk
Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its
ASMB
BenzingaSep 8, 2026, 8:17 PMBenzinga Newsdesk
Assembly Biosciences Says Assembly Bio Eligible For Up To $280M In Milestones And Royalties Outside U.S.; GS-1179 Expected To Advance Into Phase 2 Trial For Genital Herpes By End Of 2026; Assembly Bio Expects Cash Runway Into 2029
ASMB GILD
BenzingaSep 8, 2026, 8:01 PMBenzinga Newsdesk
Assembly Biosciences Announces Exercise Of Option To Share 40% Of U.S. Development Costs And Profits For Gilead-Partnered HSV Helicase-Primase Inhibitor Program In Recurrent Genital Herpes
ASMB GILD